A nationwide survey among emergency physicians and oncologists to improve the management of immune checkpoint inhibitors toxicity

Support Care Cancer. 2022 Aug;30(8):6365-6368. doi: 10.1007/s00520-022-06844-7. Epub 2022 Jan 26.

Authors

Jacopo Davide Giamello¹, Giuseppe Lauria², Andrea Antonuzzo³, Paolo Bossi⁴, Bartolomeo Lorenzati², Gianmauro Numico⁵

Affiliations

¹ School of Emergency Medicine, University of Turin, Turin, Italy. jacopo.giamello@gmail.com.
² Department of Emergency Medicine, Santa Croce e Carle Hospital, Cuneo, Italy.
³ Department of Medical Oncology, University of Pisa, Pisa, Italy.
⁴ Department of Medical Oncology, University of Brescia, Brescia, Italy.
⁵ Department of Medical Oncology, Santa Croce e Carle Hospital, Cuneo, Italy.

PMID: 35083544
DOI: 10.1007/s00520-022-06844-7

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Immune Checkpoint Inhibitors
Immunotherapy
Neoplasms* / drug therapy
Oncologists*

Substances

Immune Checkpoint Inhibitors